Green Cross Corporation (006280.KS)
KRW 168000.0
(-1.7%)
KRW 168000.0
(-1.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1103.45 Billion KRW | 15.08% |
| 2022 | 958.89 Billion KRW | -0.36% |
| 2021 | 962.38 Billion KRW | 9.1% |
| 2020 | 882.09 Billion KRW | 13.79% |
| 2019 | 775.22 Billion KRW | 29.81% |
| 2018 | 597.2 Billion KRW | 0.39% |
| 2017 | 594.86 Billion KRW | 21.01% |
| 2016 | 491.6 Billion KRW | 17.77% |
| 2015 | 417.42 Billion KRW | 1.88% |
| 2014 | 409.72 Billion KRW | 54.7% |
| 2013 | 264.85 Billion KRW | -1.59% |
| 2012 | 269.14 Billion KRW | 16.98% |
| 2011 | 230.07 Billion KRW | 15.58% |
| 2010 | 199.06 Billion KRW | -43.8% |
| 2009 | 354.2 Billion KRW | 25.52% |
| 2008 | 282.19 Billion KRW | 48.81% |
| 2007 | 189.62 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1241.42 Billion KRW | 4.25% |
| 2024 Q1 | 1190.78 Billion KRW | 7.91% |
| 2023 Q2 | 808.74 Billion KRW | -21.44% |
| 2023 Q4 | 1103.45 Billion KRW | -1.98% |
| 2023 Q3 | 1125.7 Billion KRW | 39.19% |
| 2023 FY | 1103.45 Billion KRW | 15.08% |
| 2023 Q1 | 1029.44 Billion KRW | 7.36% |
| 2022 FY | 1625.01 Billion KRW | -0.36% |
| 2022 Q4 | 958.89 Billion KRW | -7.14% |
| 2022 Q3 | 1032.66 Billion KRW | 4.21% |
| 2022 Q2 | 990.98 Billion KRW | -0.97% |
| 2022 Q1 | 1000.68 Billion KRW | 3.98% |
| 2021 Q2 | 969.89 Billion KRW | 1.83% |
| 2021 Q1 | 952.44 Billion KRW | 7.98% |
| 2021 Q4 | 962.38 Billion KRW | -0.16% |
| 2021 FY | 1586.1 Billion KRW | 9.1% |
| 2021 Q3 | 963.91 Billion KRW | -0.62% |
| 2020 Q4 | 882.09 Billion KRW | 0.49% |
| 2020 FY | 1567.7 Billion KRW | 13.79% |
| 2020 Q1 | 783.73 Billion KRW | 1.1% |
| 2020 Q2 | 871.81 Billion KRW | 11.24% |
| 2020 Q3 | 877.74 Billion KRW | 0.68% |
| 2019 Q4 | 775.22 Billion KRW | 4.03% |
| 2019 Q3 | 745.2 Billion KRW | 5.1% |
| 2019 Q1 | 647.55 Billion KRW | 8.43% |
| 2019 Q2 | 709.06 Billion KRW | 9.5% |
| 2019 FY | 1267.27 Billion KRW | 29.81% |
| 2018 Q4 | 597.2 Billion KRW | -2.03% |
| 2018 Q3 | 609.59 Billion KRW | 1.45% |
| 2018 FY | 1175.48 Billion KRW | 0.39% |
| 2018 Q1 | 593.52 Billion KRW | -0.23% |
| 2018 Q2 | 600.86 Billion KRW | 1.24% |
| 2017 Q4 | 594.86 Billion KRW | -1.04% |
| 2017 Q3 | 601.11 Billion KRW | 3.85% |
| 2017 FY | 1121.02 Billion KRW | 21.01% |
| 2017 Q1 | 493.11 Billion KRW | 0.31% |
| 2017 Q2 | 578.81 Billion KRW | 17.38% |
| 2016 Q3 | 552.09 Billion KRW | 6.44% |
| 2016 FY | 872.26 Billion KRW | 17.77% |
| 2016 Q4 | 491.6 Billion KRW | -10.96% |
| 2016 Q1 | 460.43 Billion KRW | 10.3% |
| 2016 Q2 | 518.67 Billion KRW | 12.65% |
| 2015 Q1 | 455.91 Billion KRW | 11.27% |
| 2015 Q3 | 382.89 Billion KRW | -21.54% |
| 2015 Q4 | 417.42 Billion KRW | 9.02% |
| 2015 Q2 | 487.98 Billion KRW | 7.03% |
| 2015 FY | 751.28 Billion KRW | 1.88% |
| 2014 Q4 | 409.72 Billion KRW | 1.15% |
| 2014 Q3 | 405.06 Billion KRW | 16.62% |
| 2014 FY | 609.8 Billion KRW | 54.7% |
| 2014 Q1 | 304.21 Billion KRW | 14.86% |
| 2014 Q2 | 347.33 Billion KRW | 14.17% |
| 2013 Q3 | 268.96 Billion KRW | 3.14% |
| 2013 FY | 524.45 Billion KRW | -1.59% |
| 2013 Q1 | 280.51 Billion KRW | 4.22% |
| 2013 Q2 | 260.76 Billion KRW | -7.04% |
| 2013 Q4 | 264.85 Billion KRW | -1.53% |
| 2012 Q2 | 226 Billion KRW | 7.46% |
| 2012 Q1 | 210.31 Billion KRW | -8.59% |
| 2012 FY | 473.5 Billion KRW | 16.98% |
| 2012 Q4 | 269.14 Billion KRW | 0.89% |
| 2012 Q3 | 266.78 Billion KRW | 18.04% |
| 2011 FY | 3707.45 Billion KRW | 15.58% |
| 2011 Q4 | 230.07 Billion KRW | -3.49% |
| 2011 Q3 | 238.38 Billion KRW | 9.16% |
| 2011 Q2 | 218.38 Billion KRW | -3.68% |
| 2011 Q1 | 226.73 Billion KRW | 0.0% |
| 2010 Q1 | 268.76 Billion KRW | -24.12% |
| 2010 Q3 | 244.85 Billion KRW | -2.98% |
| 2010 FY | 3271.49 Billion KRW | -43.8% |
| 2010 Q2 | 252.37 Billion KRW | -6.1% |
| 2009 Q1 | 301.65 Billion KRW | 6.89% |
| 2009 Q3 | 303.8 Billion KRW | 2.0% |
| 2009 Q2 | 297.84 Billion KRW | -1.26% |
| 2009 Q4 | 354.2 Billion KRW | 16.59% |
| 2009 FY | 2823.05 Billion KRW | 25.52% |
| 2008 Q1 | 202.16 Billion KRW | 6.61% |
| 2008 Q4 | 282.19 Billion KRW | 12.23% |
| 2008 Q3 | 251.44 Billion KRW | 18.18% |
| 2008 Q2 | 212.76 Billion KRW | 5.24% |
| 2008 FY | 2433.06 Billion KRW | 48.81% |
| 2007 FY | 2080.54 Billion KRW | 0.0% |
| 2007 Q4 | 189.62 Billion KRW | 1.66% |
| 2007 Q1 | 150.8 Billion KRW | 0.0% |
| 2007 Q2 | 179.03 Billion KRW | 18.72% |
| 2007 Q3 | 186.53 Billion KRW | 4.19% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ORIENT BIO Inc. | 11.89 Billion KRW | -9179.082% |
| Green Cross Holdings Corporation | 1856.16 Billion KRW | 40.552% |
| Green Cross Holdings Corporation | 1103.45 Billion KRW | 0.0% |
| Pharmicell Co., Ltd. | 18.79 Billion KRW | -5771.186% |
| GeneOne Life Science, Inc. | 39.51 Billion KRW | -2692.238% |
| Celltrion, Inc. | 2791.73 Billion KRW | 60.474% |
| Samsung Biologics Co.,Ltd. | 6215.7 Billion KRW | 82.247% |
| SK bioscience Co.,Ltd. | 148.58 Billion KRW | -642.645% |
| SK Biopharmaceuticals Co., Ltd. | 402.21 Billion KRW | -174.34% |
| Prestige BioPharma Limited | 196.21 Billion KRW | -462.358% |